v3.26.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash Flows from Operating Activities    
Net Loss $ (2,052,875) $ (2,693,100)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 199,553 331,719
Stock-based compensation expense 216,756 (38,174)
Allowance for doubtful accounts 7,964
Warrants issued for underwriting fee 95,984
Changes in operating assets and liabilities which used cash:    
Accounts receivable (20,598) 25,620
Prepaid expenses and other current assets (68,193) 227,768
Accounts payable (7,104) (17,970)
Accrued compensation 324,500 133,799
Deferred revenue (32,770) 3,835
Other accrued liabilities (53,240) (85,285)
Net cash and cash equivalents used in operating activities (1,486,007) (2,015,804)
Cash Flows from Investing Activities    
Investment in capitalized software (206,700) (292,199)
Net cash and cash equivalents used in investing activities (206,700) (292,199)
Cash Flows from Financing Activities    
Proceeds from the sale of common stock 3,095,950
Net cash and cash equivalents provided by financing activities 3,095,950
Net increase (decrease) in cash, cash equivalents, and restricted cash (1,692,707) 787,947
Cash, cash equivalents, and restricted cash - Beginning of period 2,433,418 2,171,016
Cash, cash equivalents, and restricted cash - End of period 740,711 2,958,963
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:    
Settle restricted stock units through common stock issuance to directors 400,000 600,000
Issuance of common stock for accrued director compensation 21,890
Issuance of common stock for public offering consulting expenses $ 655,000

Source